Logo image
Ertugliflozin decreases the insulin spike in non-insulin dysregulated standardbred horses following intra-articular triamcinolone administration
Journal article   Open access   Peer reviewed

Ertugliflozin decreases the insulin spike in non-insulin dysregulated standardbred horses following intra-articular triamcinolone administration

Cara Darch, Timothy H. Hyndman, David Byrne, David Ian Rendle and Barny Fraser
Domestic animal endocrinology, Vol.96, 107016
2026
PMID: 42056832
pdf
Published679.44 kBDownloadView
Open Access CC BY V4.0

Abstract

Hormone Insulin dysregulation SGLT2 inhibitors Steroid
Horses with equine metabolic syndrome (EMS) are at an increased risk of laminitis following corticosteroid use. Ertugliflozin reduces hyperinsulinemia in horses with EMS, and therefore may be a management option to reduce the insulin spike seen post corticosteroid use. It was hypothesised that oral ertugliflozin, administered before and after intra-articular (IA) triamcinolone acetonide (TA), will significantly lower the insulin response in comparison to placebo. A randomised, blinded, placebo-controlled, crossover design was performed on eight adult standardbred geldings with no history of laminitis. Once a day, horses were orally-administered with either 0.05 mg/kg of ertugliflozin or volume-matched placebo for four days before and four days after IA TA (18 mg) was administered into a middle carpal joint. Horses then had a two-week washout period before the same process was repeated with the alternative treatment (ertugliflozin or placebo) and opposite carpal joint injected. During the eight-day treatment periods, blood was collected each day at 8 am and 12 pm for analysis of blood insulin, glucose and triglycerides concentrations. Using Bayesian modelling, the maximum plasma insulin concentration (Cmax) for the post-TA period was 40.2 μIU/mL (95% credible interval: 13.2, 65.7) with placebo and 16.7 μIU/mL (95% CI: 1.76, 40.1) with ertugliflozin. There was a 99.13% probability that the ertugliflozin Cmax was lower than that for placebo. In conclusion, four once-daily doses of oral ertugliflozin (0.05 mg/kg) given prior to and again following IA TA administration, attenuated the rise in plasma insulin concentrations in non-insulin-dysregulated horses.[Display omitted]

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

Metrics

1 File views/ downloads
4 Record Views
Logo image